Aligned Genetics, Inc. (KOSDAQ:238120)

South Korea · Delayed Price · Currency is KRW

2,570.00

+90.00 (3.63%)

At close: Oct 30, 2026

Market Cap	36.54B -22.3%
Revenue (ttm)	16.16B -5.9%
Net Income	4.64B +39.9%
EPS	329.61 +41.9%
Shares Out	14.22M
PE Ratio	7.80
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,983
Open	2,595.00
Previous Close	2,480.00
Day's Range	2,455.00 - 2,595.00
52-Week Range	2,345.00 - 6,050.00
Beta	0.50
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About Aligned Genetics

Aligned Genetics, Inc. offers cellular imaging and biomolecular analysis solutions worldwide. It also provides molecular diagnostic solutions for rapid results under the Genescale name; and advanced imaging and analysis solutions under the Logos Biosystems name. The company was formerly known as Logos Biosystems, Inc. and changed its name to Aligned Genetics, Inc. in September 2020. Aligned Genetics, Inc. was founded in 2008 and is headquartered in Anyang-Si, South Korea. [Read more]

Industry Laboratory Analytical Instruments

Founded 2008

Employees 64

Stock Exchange KOSDAQ

Ticker Symbol 238120

Full Company Profile

Financial Performance

In 2025, Aligned Genetics's revenue was 16.02 billion, an increase of 1.51% compared to the previous year's 15.78 billion. Earnings were 2.91 billion, a decrease of -29.47%.

Financial Statements